Hai cercato la traduzione di stromal da Inglese a Sloveno

gastrointestinal stromal tumours
gastrointestinalni stromalni tumorji (gist)

gastrointestinal stromal tumour (gist)
gastrointestinalni stromalni tumor (gist – gastrointestinal stromal tumour)

gastrointestinal stromal tumours (gist).
z gastrointestinalnimi stromalnimi tumorji (gist).

the skin model may also have a stromal component layer.
model kože ima lahko tudi sloj strome.

sutent is also used in the treatment of malignant gastrointestinal stromal tumour (gist).
gist – gastrointestinal stromal tumour).

according to immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells.
imunohistokemične študije kažejo, da se timidin fosforilaza večinoma nahaja v tumorskih stromalnih celicah.

sutent will only be prescribed to you by a doctor with experience in medicines to treat renal cell cancer or gastrointestinal stromal tumours.
zdravilo sutent vam bo predpisal le zdravnik, ki ima izkušnje z zdravili za zdravljenje raka ledvičnih celic (karcinoma ledvic) oziroma stromalnih tumorjev prebavil.

in the case of colorectal tumours, 5-fu generation appears to be in large part localised in tumour stromal cells.
pri kolorektalnih tumorjih je generacija 5-fu močno lokalizirana v tumorskih stromalnih celicah.

the dying keratinocytes release mediators that begin the inflammatory cascade which acts on the cells in the dermis, particularly the stromal and endothelial cells.
odmirajoči keratinociti sprostijo posrednike, ti pa sprožijo kaskadne reakcije vnetja, ki deluje na celice v usnjici, zlasti na celice strome in endotelne celice.

in particular, regorafenib inhibits mutated kit, a major oncogenic driver in gastrointestinal stromal tumors, and thereby blocks tumor cell proliferation.
regorafenib še zlasti zavira mutirani kit, ki ima ključno vlogo v razvoju gastrointestinalnih stromalnih tumorjih, in s tem zavira proliferacijo tumorskih celic.

the safety and efficacy of regorafenib in patients below 18 years of age in the indication gastrointestinal stromal tumors (gist) have not been established.
varnost in učinkovitost regorafeniba pri bolnikih, starih do 18 let, z indikacijo za zdravljenje gastrointestinalnih stromalnih tumorjev (gist), nista bili dokazani.

in the ovary, there was an increase in sex-cord stromal tumours, tubulostromal tumours, granulosa cell tumours and luteomas in all treatment groups.
na jajčnikih so v vseh skupinah, ki so dobivale zdravilo, opazili povečanje gonadnih stromalnih tumorjev, tubulostromalnih tumorjev, tumorjev granuloznih celic in luteomov.

in vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumour (gist) cells, which express an activating kit mutation.
in vitro imatinib zavira proliferacijo in inducira apoptozo v gastrointestinalnih stromalnih tumorskih (gist) celicah, ki izražajo aktivirajočo mutacijo kit.

gastrointestinal stromal tumour (gist), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs.
gastrointestinalnega stromalnega tumorja (gist), tj. vrste raka želodca in črevesja, pri katerem celice v opornem tkivu teh organov nenadzorovano rastejo.

in preclinical studies regorafenib has demonstrated potent antitumour activity in a broad spectrum of tumour models including colorectal and gastrointestinal stromal tumour models which is mediated by its anti-angiogenic and anti-proliferative effects.
v predkliničnih študijah je regorafenib pokazal močno protitumorno delovanje pri širokem spektru tumorskih modelov, vključno z modelom kolorektalnega in gastrointestinalnega stromalnega tumorja, zaradi antiangiogenih in antiproliferativnih učinkov.

but starting in 2004, when antiangiogenic therapies first became available, well you can see that there has been a 70 to 100 percent improvement in survival for people with kidney cancer, multiple myeloma, colorectal cancer, and gastrointestinal stromal tumors.
od leta 2004, od prve uporabe antiangiogene terapije, se je, kot vidite, preživetje bolnikov podaljšalo za od 70 do 100 odstotkov za bolnike z rakom ledvic, kostnega mozga, debelega črevesa in danke ter rakom prebavil.

clinical studies the clinical safety and efficacy of sutent has been studied in the treatment of patients with malignant gastrointestinal stromal tumour (gist) who were resistant to imatinib (i. e. those who experienced disease
kliniČne Študije klinično varnost in učinkovitost sutenta so raziskali pri bolnikih z malignim gastrointestinalnim stromalnim tumorjem (gist), ki so bili odporni proti imatinibu (t. j. jim je bolezen med zdravljenjem z imatinibom ali po njem napredovala) ali imatiniba niso prenašali (t. j. so med zdravljenjem z njim imeli pomembne toksične učinke, ki so preprečili nadaljnjo terapijo), ter pri bolnikih z metastatskim karcinomom ledvičnih celic (mrcc).